E
CRL icon

Ergoteles’s Charles River Laboratories CRL Stock Holding History

Ergoteles’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,569
Closed -$330K – 224
2023
Q2 		$330K Sell
1,569
-13,519
-90% -$2.69M 0.02% 745
2023
Q1 		$3.05M Buy
15,088
+5,433
+56% +$1.23M 0.12% 162
2022
Q4 		$2.1M Buy
+9,655
New +$2.11M 0.08% 264
2022
Q1 		– Sell
-1,807
Closed -$681K – 1284
2021
Q4 		$681K Buy
+1,807
New +$702K 0.03% 529

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Ergoteles's CRL Position: Q3 2023 in Review

Ergoteles sold out of Charles River Laboratories (CRL) in Q3 2023, closing a stake of 1,569 shares — an estimated $330K sold.

Ergoteles first reported a position in CRL in Q4 2021 and held it in 4 quarters. The position peaked at $3.05M in Q1 2023. 621 funds tracked by Wall St. Rank hold CRL as of Q3 2023.

  • Ergoteles reported no remaining Charles River Laboratories position as of Q3 2023 after selling out during the quarter.
  • Ergoteles sold 1,569 Charles River Laboratories shares in Q3 2023, an estimated $330K.
  • Ergoteles first reported a position in Charles River Laboratories in Q4 2021 and held it in 4 quarters.
  • Ergoteles's Charles River Laboratories position peaked at $3.05M in Q1 2023.
  • 621 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.